TPG-backed Bicara Therapeutics raises $315 mln in US IPO (updated)

Bicara Therapeutics

13/09/2024 02:36

(Adds details from paragraph 2 onwards)
       Sept 12 (Reuters) - Bicara Therapeutics  BCAX.O  raised
$315 million in its initial public offering in the United
States, the TPG-backed cancer therapy developer said on
Thursday.
    The company priced its offering of 17.5 million shares at
$18 apiece, at the high-end of its targeted range of $16 to $18
each. The IPO values Bicara at $881.4 million.
        Bicara is among several drug developers that will test
investor appetite with their IPOs in the coming weeks. 
    The company had initially planned on selling about 11.8
million shares, but Bicara upsized the offering to 14.7 million
shares on Wednesday.
        Morgan Stanley, TD Cowen, Stifel and Cantor Fitzgerald
are the underwriters for the offering.

 (Reporting by Gnaneshwar Rajan and Arasu Kannagi Basil in
Bengaluru; Editing by Leroy Leo and Alan Barona)
 ((Gnaneshwar.Rajan@thomsonreuters.com))